Autologous Conditioned Serum - 26/10/16
, Xavier Chevalier, MD b, Peter Wehling, MD, PhD cRésumé |
Autologous conditioned serum was developed in the mid 1990s as an expeditious, practical, and relatively inexpensive means of generating the interleukin-1 receptor antagonist, a naturally occurring inhibitor of the cytokine interleukin-1. The latter is thought to be an important mediator of inflammation, pain, and tissue destruction in musculoskeletal conditions. ACS has been widely and successfully used in the local treatment of human and equine osteoarthritis and radicular compression; it has also shown promise in treating tendinopathies, muscle injuries, and tunnel widening after reconstruction of the anterior cruciate ligament. Experience suggests that autologous conditioned serum is safe and effective.
Le texte complet de cet article est disponible en PDF.Keywords : Interleukin-1 receptor antagonist, Osteoarthritis, Radicular compression, Intra-articular therapy, Anterior cruciate ligament, Tendinopathy, Muscle injury, Pain
Plan
| Disclosure Statement: C.H. Evans is a member of the Supervisory Board of Orthogen, AG that sells a device for producing autologous conditioned serum; X. Chevalier has nothing to disclose; P. Wehling is founder and CEO of Orthogen AG. |
Vol 27 - N° 4
P. 893-908 - novembre 2016 Retour au numéro
Article précédent
- Biocellular Regenerative Medicine : Use of Adipose-Derived Stem/Stromal Cells and It's Native Bioactive Matrix
- Robert W. Alexander
- ?2-Macroglobulin : Autologous Protease Inhibition Technology
- Jason M. Cuéllar, Vanessa Gabrovsky Cuéllar, Gaetano J. Scuderi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?